Note to File: A Clinical Research Podcast

From National Mac & Cheese Day to the broken economics of centralized recruitment… this Sticky Notes episode goes from nonsense to nuclear takes on how sites really handle patient recruitment. Denali and Brad dig into why so many sites are drowning in bad referrals, buried in tools, and still treating recruitment like a side quest instead of a core competency. They challenge the idea that sponsors and central vendors should own recruitment, and make the case that sites need to embrace what this really is: a sales process for motivated patients that can absolutely be done ethically. We get into: – The reality of central campaigns, garbage referrals, and "anyone will click anything" ads – Why sites complain about recruitment but won't invest dedicated people or time into it – Site-owned tech vs sponsor tech sprawl (four logins just to pre-screen? really?) – Personalized patient navigation: what it should actually look like at the site level – How AI might help pre-screening… and where patients instantly check out – The ethics of "selling" clinical trials without becoming a used car salesperson – Why high-performing sites should get more of the recruitment budget and leads Plus: – A cash-pay surgery center in Oklahoma City that might be the perfect research partner – Mac and cheese supremacy, Bastille Day, shark awareness, and why bugs are the enemy – Why coordinators shouldn't be forced to moonlight as sales reps If you run or work at a clinical research site, this one will either make you mad, motivated, or both. Want more unfiltered conversations about clinical trial operations, sites, and industry nonsense? Subscribe and check out notetofilepodcast.com for episodes, show notes, and more.

Clinical research sites are *quietly holding all the cards*—so why are they still struggling for support, fair budgets, and real partnership? In this episode of **Note to File**, Brad and Denali sit down with **Maria P. Ladd**, self-declared **Clinical Research Site Advocate** and co-founder of the **Clinical Research Site Collective**, to dig into the gap between sites, CROs, sponsors, and IRBs—and how we can finally start closing it. From **budget negotiations and profit margins** to **IRB relationships** and **site community-building**, this conversation hits the real, unfiltered pain points of running a research site in 2024 and beyond. --- In this episode, we get into: - Why Maria created the **Clinical Research Site Collective** and what "site advocacy" really means - How sites can better **leverage IRBs** as a *resource*, not just a regulator - The messy reality of **budget negotiations**, FMV, and why profit margin at sites should NOT be a dirty word - How smaller and emerging sites can survive when studies keep getting more complex - Whether we still need **local IRBs**—and what a "single IRB of record" world might look like --- Who this is for: - Independent and emerging **clinical research sites** - Site networks, AMCs, and research leaders - CRAs, project managers, and sponsor/CRO folks who *actually* want to understand sites - Anyone trying to build a more sustainable, collaborative clinical trial ecosystem --- 🔗 **Connect with Maria** LinkedIn: *Maria P. Ladd* Clinical Research Site Collective: **clinicalresearchsitecollective.com** 🎧 More episodes & contact: **NoteToFilePodcast.com**

In this episode of **Note to File**, Brad and Denali dig into: - **Why independent sites get boxed out** of imaging, colonoscopy suites, and other hospital-owned services - How **legal, IRB, compliance, and procurement** teams quietly kill otherwise great trials - The ugly reality of **Medicare coverage analysis**, double billing risk, and why millions go *unbilled* out of fear - The latest political push around **diversity in clinical trials** (and why the new rhetoric doesn't quite add up) - Whether decentralized trials and rural access actually solve the **diversity problem**—or just move it - A new multi‑agent **AI "virtual trial design team"** (informaticist, clinician, statistician, etc.) that could finally fix our worst protocols - Why **bad protocol design** is the real root cause behind "recruitment problems" and constant screen failures Mixed in: national "holidays," accidental **snail farming**, and a July lineup of guests from site collectives, payments, and tech. If you care about **independent sites**, **coverage analysis**, **DEI in trials**, and **where AI actually makes sense in clinical research**, this episode is for you. 🔔 **Subscribe** for more unfiltered conversations about clinical trial operations, site life, and the future of research. 🌐 More at **NoteToFilePodcast.com**

World UFO Day, disco, and…Operation *Trial* blazer? In this episode of **Note to File**, Brad and Denali kick things off with some classic nonsense—World UFO Day, Roswell, National Disco Day, and why U.S. soccer fandom magically appears every four years—before diving into a serious (and pretty spicy) breakdown of **clinical trial access, economics, and Operation Trailblazer**. We unpack: - Why only **3–7% of oncology patients** ever make it into a trial—even though the majority say they *would* participate - How **economic and household realities** (time off work, travel, childcare, insurance coverage) quietly gatekeep trial participation - Why **oncology, IBD, chronic pain, and derm** behave very differently when it comes to trial incentives - The tension between **protocol design vs. real-world feasibility** and whether we're making research harder than it needs to be - What **Operation Trailblazer / "Trial Blazer"** actually is, who it's really built around (QRIs, AMCs, big systems), and what that means for **community sites and site networks** - Whether government is fixing **paperwork problems or patient problems** - EHR flags, master protocols, single pivotal trials, anti‑kickback safe harbors, and why **adoption** of existing guidance may matter more than any new initiative - The weird mix of **American exceptionalism, global competition, and budget cuts** that shape U.S. research policy If you care about **site-level reality**, **patient access**, and how policy actually hits the ground (or doesn't), this one's for you. **Timestamps (approx):** 0:00 Cold open & intro 3:20 World UFO Day, aliens, and deep-sea vs deep-space 7:40 Made in the USA Day, World Cup, and U.S. soccer culture 10:15 National Disco Day & Note to File playlist ideas 11:55 Why so few oncology patients join clinical trials 16:30 Insurance, community cancer centers, and structural barriers 19:40 Are we making trials hard on purpose—or just badly? 20:50 Operation Trailblazer / "Trial Blazer" overview 23:10 Qualified Research Institutions (QRIs) & phase I focus 24:45 Could community sites do this better than AMCs? 27:00 EHR flags and why doctors mostly click past them 29:45 Participant payments, undue influence, and safe harbor 31:30 Single pivotal trials & what that means for sites 33:30 Master protocols & not reinventing the wheel 36:00 Policy, trust, and guidance no one follows 39:00 Fourth of July disco playlist & outro **Listen if you're into:** - Clinical trial operations & site strategy - Oncology and access to innovation - U.S. research policy & Operation Trailblazer - Real talk about what actually works at the site level

Is "innovation" in clinical trials just a cover for offshoring risk and cozy politics? In this episode of **Note to File**, Brad and Denali dive into two big stories shaping clinical research right now: 1. **Congress vs Big Pharma in China** - US House subcommittee letters to Merck, AbbVie, Lilly, Pfizer & more - Early-phase trials in **Chinese military hospitals** - Alleged **informed consent gaps** and **IP leakage** to the Chinese military - Is this about **ethics & patient safety**, or **America-first politics** and control? 2. **"Real-Time Trials" & the Paradigm Problem** - What the hell is *"signal-level data"* actually supposed to mean? - Why the FDA + Paradigm announcement felt like **ready, fire, aim** - Venture capital, ex-government leadership, Operation Warp Speed ties - Are we solving real problems, or just funding the best press releases? Along the way we also hit: - Work-life balance vs American grind culture (paternity leave, 4‑day work week) - National "holidays" for everything (Asteroid Day, Social Media Day… Note to File Day when?) - Clinical trials in **Minecraft** (yes, we went there) If you care about **where trials are really going**—who controls the data, who sets the rules, and who actually benefits—this one's for you. 👉 **Subscribe** for more unfiltered, independent commentary on clinical trials, sites, and the messy reality behind the headlines. 💬 Got thoughts on China trials or real-time trials? Drop them in the comments or hit us at **NoteToFilePodcast.com**.

Are we actually innovating in clinical research… or just slapping AI buzzwords on old problems? In this episode of Note to File, we go deep on: Founder-led vs board-appointed CEOs – why "benevolent dictators" might actually get more done Why eccentric weirdos sometimes make the best leaders (and the worst coworkers) The wave of AI-in-clinical-research announcements (Florence, EISF, "chat with your data," etc.) and why so much of it is just… AI slop What sites REALLY need from AI: Auto-filing ISF docs Building source from protocols Actual agentic labor, not just another chat box CTMS vs QuickBooks – why finances at research sites are still a mess The tension between running a research site like a business vs. not selling your soul to PE-backed growth-at-all-costs The rise of small, independent sites and what's actually working for them Along the way we detour through National Fudge Day, World Sea Turtle Day, and whether loving vegetables is a valid qualification for being CEO. If you're a site owner, coordinator, sponsor, CRO, or tech vendor who's tired of hype and wants unfiltered, practical talk about the future of sites + AI, this one's for you. 👉 Subscribe for more independent, no-BS conversations about clinical research. 📬 Got a topic or rant? Hit us up at NoteToFilePodcast.com

Ever wondered how hard it really is to spin up a trial on ClinicalTrials.gov? In this episode of Note to File, Brad and Denali walk through Brad's experiment: he created and submitted a trial record on ClinicalTrials.gov just to see how far it would go. Spoiler: it got published… and the feedback was mostly about formatting, not scientific or ethical rigor. We unpack: 🧾 How easy it is to create a ClinicalTrials.gov record using PRS 💻 Where AI "help" starts to blur the line between convenience and garbage data 🧪 What this means for patients who use ClinicalTrials.gov to find trials 🧨 How fake or low‑quality records could distort sponsor pipelines and vendor tools ⚖️ Recent cases of data falsification and fraud at research sites 🎰 A wild new angle: betting on clinical trial endpoints (Endpoint Arena) What are people actually wagering on? Could site staff or sponsors game the system? Are we just importing sports-betting culture into clinical research? Along the way we hit on: The gap between what ClinicalTrials.gov was designed for vs. how patients actually use it The tension between regulatory requirements, data integrity, and real-world behavior How financial incentives, recruitment vendors, and "trial search" tools shape what patients ever see If you care about trial transparency, site integrity, and the future of our ecosystem, this one's going to make you a little uncomfortable—in a good way. 🔗 Listen + subscribe: Note to File podcast – unfiltered clinical research commentary, interviews, and general nonsense for the research community. Have a topic you want us to dig into? 👉 Hit us up at NoteToFilePodcast.com

Clinical trial sites are drowning in double data entry, eSource chaos, and bad software that nobody actually wants to use. In this episode of Note to File, Brad and Denali sit down with Oliver Keh, founder of Gleam, to talk about how his team is attacking data entry and QC from a site-first perspective—no forced sponsor rollout, no "move fast and break GCP" nonsense. We get into: Why data entry isn't a tech problem – it's a vendor + workflow problem How Gleam does "fetch & fill" from any source to any EDC (without brittle APIs) The reality of eSource vs paper and why going "back to paper" is not crazy What FDA actually cares about with AI in clinical trials (fit-for-purpose + human in the loop) Why most clinical trial tech fails: developers don't sit in sites Usage-based pricing, weekly calls with coordinators, and building tools people actually use If you're a site owner, coordinator, or sponsor who's tired of being sold garbage tech, this one's for you. 🔗 Connect with Oliver / Gleam Website: joingleam.com

In this Sticky Notes episode, we riff on everything from clinical trial prediction markets (yes, literally betting on FDA approvals) to the murky world of seeding trials that look a lot more like marketing campaigns than science. We dig into: End Point Arena & trial prediction markets – paper trading today, real money tomorrow? How investors already "bet" on trial outcomes by mining clinical data for stock picks Seeding trials in phase 3/4: when "research" is really about drug exposure & provider behavior The thin ethical line: are patients being misled when trials are primarily commercial tools? IRB transparency (or lack thereof): what actually gets rejected, and who decides? The blurry crossover between R&D and commercial, from branding during trials to MSLs as quasi-sales Why most sites secretly need a sales & marketing mindset just to keep the doors open Along the way, we also hit: Conference season chaos National Cheese Day, Hug Your Cat Day, and Moonshine Day The ever-expanding definition of a "study coordinator" If you're in sites, sponsors, CROs, or pharma and you've ever wondered, "Where does science end and sales begin?"—this one's for you. 👉 Have a topic you want us to tear apart next? Drop it at NoteToFilePodcast.com

Ever wondered what's REALLY happening with your pharmacy data, how EU sites operate compared to the U.S., or whether you actually need $1.5M to start a research site? In this episode of Note to File, Brad and Denali go full sticky-note mode, bouncing from European work culture to GDPR smackdowns to the future of real‑world data and AI in clinical research. In this episode, we dig into: Copenhagen recap & EU site culture Denali's trip to the Veeva R&D & Quality EU Summit in Copenhagen Why EU sites feel more integrated with sponsors and health systems The dominance of hospital- and health system–based sites vs. U.S. independents Why true independent sites are rarer in Europe (overhead, infrastructure, and system design) Four-day workweeks, efficiency & "wage slavery" European 36-hour workweek norms in healthcare Do four-day weeks actually maintain productivity? Brad's reality check: embedded in clinics seeing patients 5 days a week Efficiency vs. butts-in-seats: "Do great work, then go live your life." IQVIA's GDPR fine & the illusion of anonymized data Breakdown of the €5M GDPR fine tied to French health data warehouses Pharmacy and EMR data used for real-world evidence and analytics Why "anonymized" often… isn't Lack of transparency, consent, and real opt-outs for patients How this parallels U.S. pharmacy data being used for recruitment and targeting Consent, terms of use & contract fatigue Are we really "consenting" when we click through IRB portals, pharmacy forms, and app updates? Contract fatigue in modern life: signing everything, reading nothing Data breaches, token identity monitoring, and what your data is apparently "worth" Site startup myths & market trends The myth that you need $1.5M to open a site vs. Brad's "a few thousand and some hustle" Summer slowdown vs. pickup in site activity, PSVs, and study awards How the current U.S. administration and policy uncertainty ripple through the pipeline Real-world data, AI, IPOs, and whether anyone actually knows what they're building All of this wrapped in the usual unfiltered, slightly chaotic, no-agenda Note to File energy—with shoutouts, side quests, and a friendly "podcast war" declaration with Steve Wimmer's new show.

In this episode of Note to File, Brad catches up with Denali live from Copenhagen as she kicks off the Veeva EU Summit—their first year meaningfully bringing sites into the mix. They dig into: -How the EU site landscape really compares to the US -Whether sites and sponsors are actually more collaborative in Europe -Why M&A and site networks look different across the pond -And the big one: what airline interoperability and air traffic control can teach clinical research about standards, data exchange, and real-time oversight Denali walks through her travel saga—from Delta to SAS to FlightAware—as a perfect analogy for how clinical trial tech breaks down the moment systems stop "speaking the same language." Brad and Denali explore why we still don't have: -A "TSA / air traffic control" equivalent for clinical trials -Minimal, shared standards for how data moves between sites, sponsors, and vendors -Real incentives to play the long game ("one marshmallow now vs. five later") on interoperability They also touch on: -GDPR and EU data laws vs. US incentives -What "meaningful use" did for healthcare data—and whether trials need their own version -Why standardizing how data is transmitted (not the IP itself) could finally unlock speed and efficiency for everyone And, of course, it wouldn't be Note to File without a little nonsense: -Opening a Lisbon site -Traveling as an American right now -And the pitch for Steve Wimmer's fractional marshmallow MLM If you care about site–sponsor relationships, global site networks, or why clinical trials still can't talk to each other in 2026, this one's for you.

Clinical trials are supposed to be science… but are they really? In this episode of Note to File, Denali and Brad riff on everything from Veeva's EU R&D Summit in Denmark to patient recruitment reality vs. industry fantasy, and end up in a pretty honest place: We're designing protocols for patients who don't exist. We dig into: -Veeva EU R&D Summit & "site day zero" -Site–sponsor collaboration in the EU -The chaos of regulations, cultures, and data sovereignty across a whole continent -AI, agents, and site efficiency -Auto‑filing IRB approvals into the ISF/TMF -Schedule builders from the protocol -eSource–EDC connectivity so sites never log into EDC again (in theory…) -Patient recruitment reality -Why mining clinic EHRs can feel creepy and low‑yield -Advertising vs. "trusted doctor referral" -Why Facebook ads can deliver more motivated patients than the clinic database -The unicorn protocol problem -Writing inclusion/exclusion for "perfect" patients just to get a clean signal -Migraine studies where BMI cutoffs exclude the real‑world population -Ethical questions: are we testing drugs on the people who will actually use them? -Are clinical trials even good science? -Lack of reproducibility across sites -Wild variation in source docs and workflows -The tension between "clean science" and messy real‑world practice Along the way we also hit: -Clinical Trials Day and the tidal wave of self‑congratulatory LinkedIn posts -Why Brad is warming up to advertising despite his embedded‑site roots -How site economics punish all the pre‑screening that doesn't enroll -Motivations for participation: altruism, access to care, and "I just trust my doctor" If you care about site operations, protocol design, and whether we're actually doing good science, this one's for you.

The retail pharmacy revolution in clinical trials didn't exactly go as advertised. So what actually happened inside Walgreens, and what does it mean for sites? In this episode of Note to File, Brad and Denali sit down with Joe O'Rourke to unpack the real story behind retail pharmacies in clinical research – what worked, what didn't, and why traditional sites are still carrying most of the load. We get into: -Joe's origin story – from metabolic research at Johns Hopkins to pharma services and sales -How he built an early digital recruitment engine that spent $2M on Facebook in 50 days -Why Walgreens entered (and stuck with) clinical trials despite brutal rumors and headlines -The BARDA head‑to‑head trial: Walgreens vs a traditional CRO on speed, quality, and scale -Where retail pharmacies actually make sense in clinical trials (and where they absolutely don't) -How private equity, giant P&Ls, and misaligned incentives shape whether these models survive The universal pain for research sites: -Slow study startup -3% overhead fights that drag for 4 months -Opaque feasibility and "prove you're a real site" bias -Why even big AMCs are losing money on research and leaving 7‑figures unbilled -The role of novel sites, standardization, and site networks in fixing startup and sustainability -A teaser for Part 2: Brad's "cornucopia" of IRB questions for Joe and WCG If you're running a site, working at a sponsor or CRO, or trying to figure out whether retail pharmacies are friend or foe, this episode will feel uncomfortably familiar.

National Tourism Day, a mystery virus on a cruise ship, WHO launches a free clinical trials course, Congress wants to ban China data, and FDA is piloting AI-enabled early phase trials. Light vibes, heavy implications. In this episode, Brad and Denali riff on how all of this actually hits sites, sponsors, and patients: In this episode we cover: WHO's new free, self-paced clinical trials course 4.5 hours, 9 themes (ethics, GCP, community engagement, operational feasibility, etc.) Is this just another GCP box-check… or something more practical for real-world sites? Pandemic preparedness & the latest cruise ship outbreak Person-to-person transmission, high fatality, and what this says about "the age of pandemics" How global standards and infrastructure (WHO, Warp Speed, etc.) either help… or fall apart House panel move to ban clinical data from China, Russia, Iran, North Korea Concerns about IP theft, ethics, and data quality vs. the real motive: geopolitics and money What happens to diversity, inclusion, and global enrollment if we shut out huge populations? FDA's push to speed R&D & the AI-enabled early phase trials pilot Mirroring Australia's clinical notification model Public comments on the AI pilot: signal vs. noise, and who's just selling their product Paradigm's role, direct-to-FDA data streaming, and whether oncology is the worst place to start Sites, CROs, and sponsors caught in the middle Are we actually making trials faster and more efficient, or just reshuffling paperwork? Why free, credible training matters for developing countries and new site staff If you care about site operations, GCP that actually means something, global data politics, AI in clinical trials, and how any of this reaches coordinators and patients, this one's for you.

Are we seriously still building source from scratch in 2025? In this episode of Note to File, Denali and Brad break down a new Tufts / CRIO paper on how sites actually prepare source and CRFs—and what the data really says about "innovation" in clinical trials. We get into the uncomfortable truth: -54% of sites are still using paper for visit source -Only 16% are using EMR/EHR to capture research data -Sponsors talk about real-time clinical trials, interoperability, AI, while sites are still living in Word docs, PDFs, and binders In this episode, we cover: -Why sites are forced to DIY source from protocol + CRF guidelines -The 6‑week lag to get critical docs from sponsors -How siloed CRO / sponsor teams make everything worse -Paper vs eSource: where electronic actually helps—and where it doesn't -Why "site-centric tech" is often just site-owned tech, not site-valuable tech -Where CTMS, finance, and eReg really do move the needle for sites -What has to change for sponsors and sites to both win If you run or work at a site, this is a reality check on where tech actually helps—and where paper is still winning by default.

The FDA just announced a bold push for real‑time clinical trials (RTCT) — including proof‑of‑concept studies, a new pilot program, and an RFI on AI-enabled tech to speed up decision‑making. But from the site and operations side, does any of this actually solve the real problems? In this Note to File episode, Denali and Brad dig into: What the FDA actually said in the recent RTCT press conference -The claim of "45% dead time" in trials – and what's really happening between last patient visit and submission -Why data streaming to FDA in real time raises huge questions about -Unclean / unadjudicated data -Unblinding risks -Sponsor exposure and control -How vendors like Paradigm and eSource / EHR data streams are being positioned as the tech backbone -Whether AI + interoperability can actually reduce timelines vs. just create new buzzwords -The disconnect between patient recruitment as the true bottleneck and this focus on data plumbing -Local vs. central IRBs, FDA commentary on IRB "modernization," and what that means for communities and oversight -Why so many people are clapping on LinkedIn while the details remain incredibly vague This is a skeptical but fair breakdown from the site-level trenches: What could RTCT get right? Where is it wildly underbaked? And what should sites, sponsors, and vendors be watching closely as the RFI window closes and the pilot program takes shape?

Walgreens is (maybe) pulling back from clinical research. CVS already bailed. Walmart and Kroger dabbled and went quiet. So what happened to the big retail pharmacy clinical trials dream—and what does it say about the future of sites and PE-backed networks? In this episode of Note to File: The Clinical Research Podcast, Denali and Brad dig into the rumors around Walgreens' clinical trial business, the earlier exits from CVS, Walmart, and Kroger, and why running trials out of retail pharmacies is a lot harder—and less lucrative—than the pitch decks made it sound. We get into: Retail pharmacies in clinical trials Why CVS launched hard and then shut it down What Walgreens actually did well (BARDA grant, active protocols, infrastructure) Why "successful trials" still may not hit Walgreens-level margins Could Walgreens have pivoted to become a recruitment vendor instead of a full site? Margins, PE, and the "this looked good in Excel" problem How clinical research looks like green space until you try to run a site Why even tens of millions in trial revenue can be a rounding error for mega-corporations What this might signal for private equity–backed site networks and consolidation Staffing reality at sites and retail pharmacies Pharmacists, techs, CRCs: burnout, turnover, and unrealistic expectations The gap between "we need people" and "we can actually hire and keep them" Why personality, adaptability, and breadth of experience beat narrow roles Vendor visits & understanding real site operations Why Brad wants more vendors to get out of the conference room and into sites How wildly different site workflows kill any idea of a "standard site" Why you can't design site tech from a closet and expect it to work LinkedIn, networking, and experience The weird over-indexing of clinical research on LinkedIn Using conversations, mentorship, and communities to shortcut the learning curve Why there's no hack for experience—but talking to more people is the closest thing If you've ever wondered why Walgreens, CVS, and other retail giants keep stepping into—and then out of—the clinical trial space, or what that means for independent sites, PE rollups, and patient access, this one's for you

Brad and Denali dive into the messy middle of clinical research tech – where sponsors, vendors, and sites all say they care about user experience and data quality, but nobody really owns the fallout. In this episode, we unpack: -The EDC email from hell: cryptic protocol strings, confusing log-ins, and why sites are constantly asking, "What study is this again?" -How sponsor configuration can make great platforms (Rave, Veeva, etc.) look terrible at the site level -The blame game between vendors, sponsors, and sites when UX goes sideways -The ongoing war: paper vs eSource vs hybrid for small and mid-sized sites -Why interoperability and remote monitoring sound awesome on paper but rarely show up in the budget -What we actually learned (and didn't) from the EHR revolution in healthcare -Why sponsors still don't care if you're on paper—as long as they get patients and data If you're a site, vendor, or sponsor who thinks you "own" user experience…this one might sting a little.

Clinical research is out here discovering cutting‑edge therapies… and still arguing about paper vs. electronic systems. Make it make sense. In this episode of Note to File, Denali and Brad get real about why so many sites are still on paper in 2026, what tech vendors get wrong, and why standardization across sponsors, sites, and systems feels like a fantasy. We cover: -Why small and mid‑size sites often don't benefit from going fully electronic -The hidden costs and risk that eSource, eConsent, and CTMS can create for sites -Continuous remote monitoring vs. old‑school, 2‑day on‑site visits -How misaligned incentives between sites, sponsors, and vendors keep us stuck -What other regulated industries (airlines, banking) figured out that we haven't -Whether standardization needs to be driven by regulators, foundations, or "big players" -And, yes, why "Big Paper" might secretly still be winning We also warm things up with: -National Documentary Day, Eggs Benedict Day, and Wear Your Pajamas to Work Day -True crime and must‑watch documentary recommendations -Tax day, LinkedIn humblebrags, and layoffs in the research world If you work at a site, sponsor, CRO, or tech vendor, this one will probably hurt a little… in a good way.

In this episode of Note to File, Brad and Denali dig into the messy realities of modern clinical research operations: The growing disconnect between cancer center administration and clinical operations How siloed academic structures make research less efficient (and more frustrating) Sponsors asking for constant E‑source access and screenshots (!?) The coming wave of continuous data streams (EHR, eSource, ePRO, wearables) and what that means for site workload Why the complexity of clinical trials is a feature, not a bug—and why sites should be paid accordingly EPRO in the real world: who's actually watching the data, and what do patients think is happening? Budgets, holdbacks, renegotiations, and the misaligned incentives between sites, CROs, and sponsors If you work at a site, sponsor, or CRO and feel like expectations keep going up while budgets stay flat, this one's for you. 👉 Subscribe for more unfiltered conversations about clinical research, from people actually doing the work